Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Asian Journal of Animal Sciences
Year: 2011  |  Volume: 5  |  Issue: 3  |  Page No.: 213 - 218

Successful Treatment of Stanozolol Induced-hepatotoxicity with Silymarin in a Bitch

B. Mosallanejad, R. Avizeh and H. Najafzadeh Varzi    

Abstract: The aim of this study was to detect of the protective action of silymarin on stanozolol-induced-hepatotoxicity in a bitch. A female dog with age 2.5 years-old, Doberman pinscher breed and weighing 24.15 kg was presented to Veterinary Hospital of Shahid Chamran University, in August 2010, with a history of depression, salivation, vomiting and seizures. Conjunctival hyperemia and dilated retinal vessels were main clinical signs. Stanozolol had been administered 24 h ago with high dose (2.5 times maximum dose) by owner. Blood sample was collected from the cephalic vein. Serum enzyme concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total and direct bilirubin, Blood Urea Nitrogen (BUN) and creatinine levels were measured immediately after referring, as indices of liver and kidney injuries. Administration of stanozolol was caused elevatation of serum enzyme concentrations of ALT, AST, ALP, LDH, total and direct bilirubin in the affected dog. Silymarin (Sigma-Aldrich Co., St Louis, MO, USA) at a single dose of 30 mg/kg with other supportive treatments (fluid therapy and vitamin B. complex) were administered immediately. Application of silymarin improved clinical status and serum value enzyme activity was within normal, 24 h after treatment. Oral silymarin could prevent hepatotoxicity due to stanozolol in a dog.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility